Azevan Pharmaceuticals, Inc.

The United States of America As Represented by the Secretary of

The United States of America As Represented by the Department of Health

Pisces Therapeutics, LLC

Tel Aviv University

Montana State University

Ramot University Authority for Applied Research and Industrial Development Limited

N-gene Research Laboratories, Inc.

Austin Health

Intrinsic Lifesciences LLC

Michael Jay Brownstein

James Howard Wikel

Yoel Kloog

Stephen B Leighton

Mark Westerman

Lawrence C Mahan

Joab Chapman

J Stephen Fink

Liat Goldberg

Beth J Hoffman

Rafael Bruck

Jon Marsh

Eva Mezey

Shimon Reif

John Prowle

Dimitrius Karussis

Monika Konig

Rinaldo Bellomo

Frances Brenda Lefcort

John D Carpten

Jeffrey R Smith

Compounds, and compositions, methods, and uses thereof, are described herein for treating brain injuries.

Compositions and methods for treating brain injury

Compounds, and compositions, methods, and uses thereof, are described herein for treating neurodegenerative diseases and disorders. In particular, vasopressin receptor modulators, and compositions, methods and uses thereof, are described herein for treating neuropsychiatric aspects of neurodegenerative diseases such as Huntington's Disease, Parkinson's Disease, and Alzheimer's Disease.

Compositions and methods for treating neurodegenerative diseases

Compounds and compositions are described herein for treating post traumatic stress disorder.

Methods for treating post traumatic stress disorder

Disclosed is the use of O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime (BGP15), its tautomers, enantiomers and pharmaceutically acceptable salts thereof for the treatment of Familial Dysaustonomia.

Use of BGP15 to treat familial dysautonomia

The present disclosure describes new inhibitors or antagonists of Ras useful for the treatment of conditions resulting from Ras-induced or mediated cellular processes, including cellular proliferation, differentiation, apoptosis, senescence, and survival. These cellular processes may be associated with a non-malignant or malignant disease, disorder, or pathological condition. The present disclosure also describes a method for inhibiting such Ras-induced or mediated cellular processes. The method entails administering a Ras antagonist in an amount effective to inhibit such cellular processes.

Malignant and non-malignant disease treatment with Ras antagonists

Provided are methods and compositions for predicting the development of kidney disease, including acute kidney injury. In certain aspects and embodiments the provided methods and compositions are particularly useful for predicting kidney injury following an event likely to cause kidney injury and/or kidney failure in a patient, such as a cardiac surgery, e.g., a surgery involving a cardiopulmonary bypass (CPB), such as a coronary artery bypass graft surgery. In some embodiments, the higher the urinary hepcidin-to-urinary creatinine ratio (uHep/uCr) at 6-24 hours following initiation of CPB, the lower is the risk for development of AKI determined by RIFLE criteria in the ensuing four to five days. Conversely, the higher the urinary NGAL to urinary creatinine ratio (uNGAL/uCr) at 6-24 hours following initiation of CPB, the higher is the risk of developing CPB-mediated AKI over the same time period.

Markers for acute kidney injury

Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2DG are also disclosed.

Cancer treatment using FTS and 2-deoxyglucose

Disclosed is a method for inhibiting Ras-induced or mediated proliferation of cells associated with a non-malignant disease, disorder or pathological condition. The method entails administering to a patient a Ras antagonist in an amount effective to inhibit the proliferation. The invention is particularly applicable to diseases characterized by a proliferation of T-cells such as autoimmune disease, e.g., type 1 diabetes, lupus and multiple sclerosis, and pathological states such as graft rejection induced by the presentation of a foreign antigen such as a graft in response to a disease condition (e.g., kidney failure). Other non-malignant diseases characterized by proliferations of cells include cirrhosis of the liver and restenosis. Preferred Ras antagonists are S-trans-trans farnesylthiosalicylic acid (FTS) and structurally related compounds (or analogs) thereof.

Non-malignant disease treatment with Ras antagonists

Sequence modification of oligonucleotide primers to manipulate

The present invention relates, in general, to a method of identifying ligands and antagonists of ligands. In particular, the present invention relates to a method of identifying ligands and antagonists of ligands which bind to cloned G.sub.8 - or G.sub.1 -coupled receptors. The present invention also relates to a cell that comprises a recombinant cyclic AMP sensitive reporter construct.

Method of identifying ligands and anatgonists of G-protein coupled

Growing community of inventors

Rockville, MD, United States of America

Michael Jay Brownstein